MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. The company is headquartered in Woonsocket, Rhode Island. The firm and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The firm's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.
Follow-Up Questions
Multicell Technologies Inc의 CEO는 누구입니까?
Mr. W. Gerald Newmin은 1995부터 회사에 합류한 Multicell Technologies Inc의 Chairman of the Board입니다.
MCET 주식의 가격 성능은 어떻습니까?
MCET의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Multicell Technologies Inc의 주요 사업 주제나 업종은 무엇입니까?
Multicell Technologies Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
